3M Co., Branded Pharmaceutical Business in North & Latin America Sustainability Profile
3M Company, a global leader in innovation, operates its Branded Pharmaceutical Business primarily in North and Latin America, with its headquarters located in the United States. Founded in 1902, 3M has established a strong presence in the healthcare industry, focusing on developing advanced pharmaceutical solutions that enhance patient care. The Branded Pharmaceutical Business offers a diverse range of products, including prescription medications and specialty pharmaceuticals, distinguished by their commitment to quality and efficacy. 3M's unique approach combines cutting-edge technology with a deep understanding of patient needs, positioning the company as a trusted name in healthcare. With a robust market position, 3M has achieved notable milestones, including significant advancements in drug delivery systems and a strong portfolio of patented products. This dedication to innovation and excellence continues to drive 3M's success in the competitive pharmaceutical landscape.
DitchCarbon Score
How does 3M Co., Branded Pharmaceutical Business in North & Latin America's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
3M Co., Branded Pharmaceutical Business in North & Latin America's score of 14 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
As of the latest available data, 3M Co., Branded Pharmaceutical Business in North & Latin America does not report specific carbon emissions figures, as there is no emissions data provided. The organisation's climate commitments and reduction initiatives are also not detailed, indicating a lack of publicly available targets or achievements in this area. It is important to note that emissions data and climate initiatives for 3M Co. in this context are cascaded from Bausch Health Companies Inc., with a cascade level of 3. This means that any climate-related commitments or performance metrics would be inherited from Bausch Health, which may have its own set of targets and initiatives. Given the absence of specific emissions data and reduction targets, it is unclear how 3M Co. is addressing its carbon footprint or contributing to climate action within the pharmaceutical sector in North and Latin America. The lack of information highlights a potential area for improvement in transparency regarding environmental impact and sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
How Carbon Intensive is 3M Co., Branded Pharmaceutical Business in North & Latin America's Industry?
How Carbon Intensive is 3M Co., Branded Pharmaceutical Business in North & Latin America's Location?
3M Co., Branded Pharmaceutical Business in North & Latin America's Scope 3 Categories Breakdown
3M Co., Branded Pharmaceutical Business in North & Latin America's Scope 3 emissions, which increased by 41% last year and increased by approximately 41% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 21% of total emissions under the GHG Protocol, with "Waste Generated in Operations" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
3M Co., Branded Pharmaceutical Business in North & Latin America's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
3M Co., Branded Pharmaceutical Business in North & Latin America has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
